Besides ZD2, other EDB-FN-targeting ligands, antibodies and nanobodies, including APT-FN-EDB, L19, BC1, and NJB2 have also been used to deliver therapeutic and imaging agents to tumor ECM and vasculature 46, 73-75, validating the role of EDB-FN as a promising oncomarker. This evidence concerns the gene FN1 and neoplasm.